March 21, 2018Open Access

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Motzer et al. (Wed,) studied this question.

synapsesocial.com/papers/69d8d0f617a1cc0598d189f6 https://doi.org/https://doi.org/10.1056/nejmoa1712126

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study2017 · 509 citations
2THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL1934 · 4,758 citations
3Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma2007 · 5,758 citations
4Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma2009 · 491 citations
5Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis2007 · 695 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo